GURUFOCUS.COM » STOCK LIST » Oceania » Australia » ASX » Vectus Biosystems Ltd (ASX:VBS) » Definitions » LT-Debt-to-Total-Asset
Switch to:

Vectus Biosystems (ASX:VBS) LT-Debt-to-Total-Asset

: 0.00 (As of Dec. 2022)
View and export this data going back to 2016. Start your Free Trial

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vectus Biosystems's long-term debt to total assests ratio for the quarter that ended in Dec. 2022 was 0.00.

Vectus Biosystems's long-term debt to total assets ratio stayed the same from Dec. 2021 (0.00) to Dec. 2022 (0.00).


Vectus Biosystems LT-Debt-to-Total-Asset Historical Data

The historical data trend for Vectus Biosystems's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
LT-Debt-to-Total-Asset
Premium Member Only Premium Member Only - 10.11 2.40 1.19 0.02

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
LT-Debt-to-Total-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 1.19 - 0.02 -

Vectus Biosystems LT-Debt-to-Total-Asset Calculation

Vectus Biosystems's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2022 is calculated as

LT Debt to Total Assets (A: Jun. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2022 )/Total Assets (A: Jun. 2022 )
=0.07/3.936
=

Vectus Biosystems's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (Q: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2022 )/Total Assets (Q: Dec. 2022 )
=0/5.85
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Vectus Biosystems LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Vectus Biosystems logo
Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines